Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer

Dysregulated receptor tyrosine kinase c-Met and its ligand HGF is valid and attractive molecular target for therapeutic blockade in cancer. Inspired by the chemical structure of the naturally occurring olive secoiridoid (−)-oleocanthal (1) and its documented anticancer activity against c-Met-depende...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2016-08, Vol.118, p.299-315
Main Authors: Mohyeldin, Mohamed M., Busnena, Belnaser A., Akl, Mohamed R., Dragoi, Ana Maria, Cardelli, James A., El Sayed, Khalid A.
Format: Article
Language:English
Subjects:
Anti-invasive
Antimigratory
Antiproliferative
Breast cancer
c-Met
Homovanillyl sinapate
Olive secoiridoids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dysregulated receptor tyrosine kinase c-Met and its ligand HGF is valid and attractive molecular target for therapeutic blockade in cancer. Inspired by the chemical structure of the naturally occurring olive secoiridoid (−)-oleocanthal (1) and its documented anticancer activity against c-Met-dependent malignancies, a previous study reported tyrosol sinapate (4) as a c-Met inhibitor hit. This study reports additional semisynthetic optimization and SAR of 4 to improve its selective activity against c-Met-dependent breast cancer by increasing its capacity to inhibit c-Met phosphorylation. Forty-three compounds (5–47) were synthesized, among which the novel analog homovanillyl sinapate (HVS-16) was distinguished for its remarkable activity. HVS-16 substantially impaired c-Met-mediated proliferation, migration, and invasion across human breast cancer cell lines in two- and three-dimensional culture systems, while similar treatment doses were found to have effect neither on the non-tumorigenic human mammary epithelial cell growth nor on the c-Met independent breast cancer cell viability. HVS-16 showed a dose-dependent inhibition of ligand-mediated c-Met activation in human breast cancer cells. Docking studies revealed that HVS-16 fits very well inside c-Met crystal structures, satisfying critical interactions at the ATP binding site. This study identified important structural pharmacophoric features in HVS-16 and correlated its postulated binding pose with c-Met kinase assay data that would guide future olive secoiridoid bioisostere lead design. Results presented herein suggest HVS-16 as a promising c-Met inhibitor validated hit with potential to control invasive breast malignancies with aberrant c-Met activity. [Display omitted] •Inspired by (−)-oleocanthal, HVS-16 was discovered as a novel c-Met inhibitor hit.•HVS-16 impaired Met-mediated cellular events across 2D & 3D breast cancer cultures.•HVS-16 had no effect on both non-cancerous and Met-independent breast cancer cells.•Inhibition of c-Met activation was confirmed by Western blot and docking studies.
ISSN:0223-5234
1768-3254
1768-3254
DOI:10.1016/j.ejmech.2016.04.043